2-amino-2-[(4-hydroxyphenyl)methyl]butanoic acid | 2014-45-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 2-amino-2-[(4-hydroxyphenyl)methyl]butanoic acid
• 英文别名: 2-amino-2-(4-hydroxybenzyl)butanoic acid
• CAS: 2014-45-1
• 化学式: C₁₁H₁₅NO₃
• 分子量: 209.245
• InChiKey: KEFQVZYLTYLBRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  83.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-ethyl-5-(4-hydroxy benzyl) hydantoin 在 氢溴酸 作用下， 生成 2-amino-2-[(4-hydroxyphenyl)methyl]butanoic acid
  参考文献：
  名称：

  酪氨酸羟化酶抑制剂。取代的芳香族氨基酸的合成和活性。

  摘要：

  DOI：

  10.1021/jm00318a005

文献信息

• [EN] DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE<br/>[FR] INHIBITEURS DE DÉCARBOXYLASE POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON
  申请人：KINTAI THERAPEUTICS INC

  公开号：WO2020118163A1

  公开（公告）日：2020-06-11

  Provided are inhibitors of pathogenic, bacterial metabolite production and conjugates of the inhibitors. Also provided are pharmaceutical compositions containing the inhibitors or conjugates and methods of using the same.

  提供了抑制病原体、细菌代谢产物生产的抑制剂以及抑制剂的共轭物。还提供了含有抑制剂或共轭物的药物组合物以及使用它们的方法。
• Diagnostic and therapeutic agents
  申请人：Taube Seija

  公开号：US20070258899A1

  公开（公告）日：2007-11-08

  Tumor targeting units are disclosed which have a peptide sequence C y —Y—G-F—X—W-G-Z-C yy (SEQ ID NO: 25), or a pharmaceutically or physiologically acceptable salt thereof. Tumor targeting agents are also disclosed having at least one targeting unit, directly or indirectly coupled to at least one effector unit. Diagnostic or pharmaceutical compositions having at least one targeting unit or at least one targeting agent, and targeting units or targeting agents for the preparation of a medicament for the treatment of cancer related diseases (including cancer), especially for the treatment of colon/colorectal cancer or its metastases are also disclosed.

  揭示了具有肽序列Cy—Y—G-F—X—W-G-Z-Cyy（序列ID编号：25）或其药学或生理上可接受的盐的肿瘤靶向单元。还披露了具有至少一个靶向单元的肿瘤靶向剂，直接或间接地偶联至至少一个效应单元。还披露了具有至少一个靶向单元或至少一个靶向剂的诊断或药物组合物，以及用于制备治疗癌症相关疾病（包括癌症）的药物的靶向单元或靶向剂，特别是用于治疗结肠/结直肠癌或其转移的靶向单元或靶向剂。
• MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS
  申请人：Seattle Genetics, Inc.

  公开号：US20130123465A1

  公开（公告）日：2013-05-16

  Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.

  提供了MeVal-Val-Dil-Dap-Phe（MMAF）的Auristatin肽类类似物，其具有C-末端苯丙氨酸残基侧链替换或修饰，可单独提供或通过各种连接剂连接到配体上。相关的结合物可以定向特定的细胞类型，以提供治疗效益。
• Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus
  申请人：Seattle Genetics, Inc.

  公开号：US10000555B2

  公开（公告）日：2018-06-19

  Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.

  提供的 MeVal-Val-Dil-Dap-Phe (MMAF) Auristatin 肽类似物具有 C 端苯丙氨酸残基侧链替换或修饰，可单独提供或通过各种连接体连接到配体上。相关共轭物可靶向特定细胞类型，提供治疗效果。
• DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE
  申请人：Senda Biosciences, Inc.

  公开号：EP3891122A1

  公开（公告）日：2021-10-13